Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The discovery of antagonistic interactions between A2Aadenosine receptors and D2dopamine receptors in the ventral striatum suggested that A2Areceptor activation might modulate the antipsychotic effects of dopamine receptor antagonists and could provide an opportunity for the development of A2Areceptor agonists as novel antipsychotic drugs. However, there is limited evidence from preclinical and clinical studies that A2Areceptor agonists can exert antipsychotic effects. Furthermore, it remains unclear whether A2Areceptor agonists possess a sufficient safety margin or whether their potent hypotensive effects or extrapyramidal side effects would limit their therapeutic utility as antipsychotic agents. The interaction between A2Areceptors and D2receptors also raises the possibility that A2Areceptor antagonists, which hold considerable promise as antiparkinsonian agents, may have dose-limiting psychotomimetic side effects. Preclinical studies using selective A2Areceptor antagonists suggest that this class of compound has a low propensity to elicit psychotomimetic side effects or exacerbate those induced by D2receptor agonists.


Journal article



Publication Date